WAM
ESPR

Weiss Asset Management’s Esperion Therapeutics ESPR Stock Holding History

Weiss Asset Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.68M Buy
+847,118
New +$2.37M 0.03% 302
2018
Q3 		– Sell
-5,427
Closed -$213K – 206
2018
Q2 		$213K Hold
5,427
– – 0.02% 137
2018
Q1 		$393K Hold
5,427
– – 0.03% 129
2017
Q4 		$357K Buy
+5,427
New +$292K 0.03% 149

Other funds holding ESPR

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Weiss Asset Management's ESPR Position: Q2 2026 in Review

Weiss Asset Management opened a new position in Esperion Therapeutics (ESPR) in Q2 2026: 847,118 shares worth $2.68M. The stake represents 0.03% of the portfolio and ranks #302 among its holdings. This is a return to the name: Weiss Asset Management previously reported a position in ESPR as recently as Q2 2018.

Weiss Asset Management first reported a position in ESPR in Q4 2017 and has held it in 4 quarters since. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • Weiss Asset Management held 847,118 shares of Esperion Therapeutics worth $2.68M as of Q2 2026.
  • Esperion Therapeutics was a new Weiss Asset Management position in Q2 2026.
  • Esperion Therapeutics made up 0.03% of Weiss Asset Management's portfolio in Q2 2026, its #302 holding.
  • Weiss Asset Management first reported a position in Esperion Therapeutics in Q4 2017 and has held it in 4 quarters since.
  • 191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Weiss Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.